Decision-making analysis for selection of antibiotic treatment in intra-abdominal infection using preference measurements

Surgical Infections

Volumn 7, Issue 5, 2006, Pages 453-462

  Sanabria, Alvaro ^a  

^a HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFOTETAN; CEFOXITIN; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; CLINDAMYCIN; ERTAPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TICARCILLIN;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ANAPHYLACTIC SHOCK; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLIC; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; EPIGASTRIC PAIN; FEVER; FLACCID PARALYSIS; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; GLOSSITIS; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE REACTION; MEDICAL DECISION MAKING; MOOD; MUSCLE WEAKNESS; MYDRIASIS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RATING SCALE; SEIZURE; SENSITIVITY ANALYSIS; SEPSIS; SIDE EFFECT; SURGEON; SYMPTOM; SYSTEMATIC REVIEW; TASTE DISORDER; UNSPECIFIED SIDE EFFECT; VERTIGO; VOMITING;

ABDOMINAL ABSCESS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; DECISION MAKING; HUMANS;

EID: 33845264597     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2006.7.453     Document Type: Article

References (76)

1. Sanabria A, Jaime M, Aristizabal H. Experiencia quirúrgica de la sección de cirugía general de la Universidad de Antioquia-Hospital Universitario San Vicente de Paúl. Rev Colomb Cirugia 2002;17:199-206.
2. Schein, M, Marshall, J. Source Control. Heidelberg: Springer, 2003.
3. Mosdell D, Morris D, Voltura. A. Antibiotic treatment for surgical peritonitis. Ann Surg 1991,214:543-549.
4. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003;37:997-1005.
5. Mazuski JE. The Surgical Infection Society Guidelines on Antimicrobial Therapy for Intra-Abdominal Infections: Evidence for the recommendations. Surg Infect 2002;3:175-233.
6. Fletcher R, Fletcher S, Wagner E. Clinical Epidemiology: The Essentials. Baltimore: Williams and Wilkins, 1996:75-93.
7. Mandell G, Bennet J, Dolin R. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Seventh edition. New York: Churchill-Livingstone, 2000.
8. Edson RS, Terrell CL. The aminoglycosides. Mayo Clin Proc 1999;74:519-528.
9. Hellinger WC, Brewer NS. Carbapenems and monobactams: Imipenem, meropenem, and aztreonam. Mayo Clin Proc 1999;74:420-434.
10. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc 1999;74:825-833.
11. Marshall WF, Blair JE. The cephalosporins. Mayo Clin Proc 1999; 74:187-195.
12. Bailey JA, Virgo KS, DiPiro JT, et al. Aminoglycosides for intra-abdominal infection: Equal to the challenge? Surg Infect 2002;3:315-335.
13. Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003;52:538-542.
14. Hospital Universitario San Ignacio. San Ignacio hoy. Boletin cientifico e informativo. 2004.
15. Walker AP, Nichols RL, Wilson RF, et al. Of a betalactamase inhibitor combination for serious intra-abdominal infections. Ann Surg 1993;217:115-121.
16. Solomkin JS, Yellin AE, Rotstein OD, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections: Results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237:235-245.
17. Cohn SM, Lipsett PA, Buchman TG, et al. Comparison of intravenous/ oral ciprofloxacin plus metronidazole versus piperacillin/tazobactam in the treatment of complicated intra-abdominal infections. Ann Surg 2000;232:254-262.
18. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in treatment of severe generalized peritonitis: A multicenter randomized controlled trial. The Severe Generalized Peritonitis Study Group. Antimicrob Agents Chemother 2000;44:2028-2033.
19. Ohlin B, Cederberg A, Forssell H, et al. Piperacillin/tazobactam compared with cefuroxime/metronidazole in the treatment of intra-abdominal infections. Eur J Surg 1999;165:875-884.
20. Jaccard C, Troillet N, Harbarth S, et al. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998;42: 2966-2972.
21. Shyr YM, Lui WY, Su CH, et al. Piperacillin/tazobactam in comparison with clindamycin plus gentamicin in the treatment of intra-abdominal infections. Zhonghua Yi Xue Za Zhi (Taipei) 1995;56:102-108.
22. Anonymous. Results of the North American trial of piperacillin/ tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/ Tazobactam Intra-abdominal Infection Study Group. Eur J Surg 1994;(Suppl):61-66.
23. Niinikoski J, Havia T, Alhava E, et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections. Surg Gynecol Obstet 1993;176:255-261.
24. Eckhauser FE, Knol JA, Raper SE, et al. Efficacy of two comparative antibiotic regimens in the treatment of serious intra-abdominal infections: Results of a multicenter study. Clin Ther 1992;14:97-109.
25. Brismar B, Malmborg AS, Tunevall G, et al. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-2773.
26. Torres AJ, Valladares LD, Jover JM, et al. Cefminox versus metronidazole plus gentamicin in intra-abdominal infections: A prospective randomized controlled clinical trial. Infection 2000;28:318-322.
27. Luke M, Iversen J, Sondergaard J, et al. Cephtriaxone/metronidazole is more effective than ampicillin/netilmicin/metronidazole in the treatment of bacterial peritonitis. Eur J Surg 1991;157:397-401.
28. Anonymous. A randomized multicentre trial of pefloxacin plus metronidazole and gentamicin plus metronidazole in the treatment of severe intra-abdominal infections. Report from a Swedish Study Group. J Antimicrob Chemother 1990;26(Suppl B): 173-180.
29. Yellin AE, Hassett JM, Fernandez A, et al. Ertapenem monotherapy versus combination therapy with ceftriaxone plus metronidazole for treatment of complicated intra-abdominal infections in adults. Int J Antimicrob Agents 2002;20:165-173.
30. Wilson SE. Results of a randomized, multicenter trial of meropenem versus clindamycin/tobramycin for the treatment of intra-abdominal infections. Clin Infect Dis 1997;24(Suppl 2):S197-S206.
31. Dougherty SH, Sirinek KR, Schauer PR, et al. Ticarcillin/clavulanate compared with clindamycin/gentamicin (with or without ampicillin) for the treatment of intra-abdominal infections in pediatric and adult patients. Am Surg 1995;61:297-303.
32. Greenberg RN, Cayavec P, Danko LS, et al. Comparison of cefoperazone plus sulbactam with clindamycin plus gentamicin as treatment for intra-abdominal infections. J Antimicrob Chemother 1994;34: 391-401.
33. Sirinek KR, Levine BA. A randomized trial of ticarcillin and clavulanate versus gentamicin and clindamycin in patients with complicated appendicitis. Surg Gynecol Obstet 1991;172(Suppl):30-35.
34. Poenaru D, De Santis M, Christou NV. Imipenem versus tobramycin-anti-anaerobe antibiotic therapy in intra-abdominal infections. Can J Surg 1990;33:415-422.
35. Fink MP, Helsmoortel CM, Arous EJ, et al. Comparison of the safety and efficacy of parenteral ticarcillin/clavulanate and clindamycin/ gentamicin in serious intra-abdominal infections. J Antimicrob Chemother 1989;24(Suppl B):147-156.
36. Birolini D, Moraes MF, de Souza OS. Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections. Chemotherapy 1989;35(Suppl 1):49-57.
37. Stellato TA, Danziger LH, Hau T, et al. Moxalactam vs tobramycin-clindamycin: A randomized trial in secondary peritonitis. Arch Surg 1988;123:714-717.
38. Gonzenbach HR, Simmen HP, Amgwerd R. Imipenem. (N-F-thienamycin) versus netilmicin plus clindamycin: A controlled and randomized comparison in intra-abdominal infections. Ann Surg 1987; 205:271-275.
39. Nicolle LE, Harding GK, Louie TJ, et al. Cefoxitin plus tobramycin and clindamycin plus tobramycin: A prospective randomized comparison in the therapy of mixed aerobic /anaerobic infections. Arch Surg 1986;121:891-896.
40. Malangoni MA, Condon RE, Spiegel CA. Treatment of intra-abdominal infections is appropriate with single-agent or combination antibiotic therapy. Surgery 1985;98:648-655.
41. Walters DJ, Solomkin JS, Paladino JA. Cost effectiveness of ciprofloxacin plus metronidazole versus imipenem-cilastatin in the treatment of intra-abdominal infections. Pharmacoeconomics 1999;16:551-561.
42. Solomkin JS, Reinhart HH, Dellinger EP, et al. Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group. Ann Surg 1996;223:303-315.
43. Hoogkamp-Korstanje JA. Ciprofloxacin vs. cefotaxime regimens for the treatment of intra-abdominal infections. Infection 1995;23:278-282.
44. Yoshioka K, Youngs DJ, Keighley MR. A randomised prospective controlled study of ciprofloxacin with metronidazole versus amoxicillin/clavulanic acid with metronidazole in the treatment of intra-abdominal infection. Infection 1991;19:25-29.
45. Starakis I, Karravias D, Asimakopoulos, C, et al. Results of a prospective, randomized, double blind comparison of the efficacy and the safety of sequential ciprofloxacin (intravenous/oral) + metronidazole (intravenous/oral) with ceftriaxone (intravenous) + metronidazole (intravenous/oral) for the treatment of intra-abdominal infections. Int J Antimicrob Agents 2003;21:49-57.
46. Sethi K, Diamond LH. Aminoglycoside nephrotoxicity and its predictability. Nephron 1981;27:265-270.
47. Wiland P, Szechcinski J. Proximal tubule damage in patients treated with gentamicin or amikacin. Pol J Pharmacol 2003;55:631-637.
48. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999;43:1549-1555.
49. Hitt CM, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of once-daily aminoglycoside administration. Pharmacotherapy 1997;17:810-814.
50. Bertino JS Jr, Booker LA, Franck PA, et al. Incidence of and significant risk factors for aminoglycoside-associated nephrotoxicity in patients dosed by using individualized pharmacokinetic monitoring. J Infect Dis 1993;167:173-179.
51. Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986;153: 1062-1068.
52. Lam YW, Arana CJ, Shikuma LR, Rotschafer JC. The clinical utility of a published nomogram to predict aminoglycoside nephrotoxicity. JAMA 1986;255:639-642.
53. Schentag JJ, Plaut ME, Cerra FB. Comparative nephrotoxicity of gentamicin and tobramycin: Pharmacokinetic and clinical studies in 201 patients. Antimicrob Agents Chemother 1981;19:859-866.
54. French MA, Cerra FB, Plaut ME, Schentag JJ. Amikacin and gentamicin accumulation pharmacokinetics and nephrotoxicity in critically ill patients. Antimicrob Agents Chemother 1981;19:147-152.
55. Giamarellou H, Metzikoff C, Papachristophorou S, et al. Prospective comparative evaluation of gentamicin or gentamicin plus cephalothin in the production of nephrotoxicity in man. J Antimicrob Chemother 1979;5:581-590.
56. Plaut ME, Schentag JJ, Jusko WJ. Aminoglycoside nephrotoxicity: Comparative assessment in critically ill patients. J Med 1979;10:257-266.
57. Lerner SA, Seligsohn R, Matz GJ. Comparative clinical studies of ototoxicity and nephrotoxicity of amikacin and gentamicin. Am J Med 1977 62:919-923.
58. Lerner SA, Schmitt BA, Seligsohn R, Matz GJ. Comparative study of ototoxicity and nephrotoxicity in patients randomly assigned to treatment with amikacin or gentamicin. Am J Med 1986;80:98-104.
59. Barza M, Lauermann MW, Tally FP, Gorbach SL. Prospective, randomized trial of netilmicin and amikacin, with emphasis on eighth-nerve toxicity. Antimicrob Agents Chemother 1980;17:707-714.
60. Kahlmeter G, Dahlager JI. Aminoglycoside toxicity: A review of clinical studies published between 1975 and 1982. J Antimicrob Chemother 1984;13(Suppl A):9-22.
61. Nordstrom L, Ringberg H, Cronberg S, et al. Does administration of an aminoglycoside in a single daily dose affect its efficacy and toxicity? J Antimicrob Chemother 1990;25:159-173.
62. Moore RD, Lerner SA, Levine DP. Nephrotoxicity and ototoxicity of aztreonam versus aminoglycoside therapy in seriously ill nonneutropenic patients. J Infect Dis 1992;165:683-688.
63. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995;39:650-655.
64. Neu HC, Prince A, Neu CO, Garvey GJ. Incidence of diarrhea and colitis associated with clindamycin therapy. J Infect Dis 1977;135(Suppl):S120-125.
65. Lusk RH, Fekety FR Jr, Silva J Jr, et al. Gastrointestinal side effects of clindamycin and ampicillin therapy. J Infect Dis 1977;135(Suppl):S111-S119.
66. Condon RE, Anderson MJ. Diarrhea and colitis in clindamycin-treated surgical patients. Arch Surg 1978; 113:794-797.
67. Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: Preliminary results of a cooperative study. J Infect Dis 1977; 135(Suppl):S104-S110.
68. Segev S, Yaniv I, Haverstock D, Reinhart H. Safety of long-term therapy with ciprofloxacin: Data analysis of controlled clinical trials and review. Clin Infect Dis 1999;28:299-308.
69. Schacht P, Arcieri G, Hullmann R. Safety of oral ciprofloxacin. An update based on clinical trial results. Am J Med 1989;87:98S-102S.
70. Arcieri GM, Becker N, Esposito B, et al. Safety of intravenous ciprofloxacin. A review. Am J Med 1989; 87:92S-97S.
71. Rahm V, Schacht P. Safety of ciprofloxacin: A review. Scand J Infect Dis 1989;Suppl 60:120-128.
72. Sarti W. Routine use of skin testing for immediate penicillin allergy to 6,764 patients in an outpatient clinic. Ann Allergy 1985;55:157-161.
73. Kerr JR. Penicillin allergy: A study of incidence as reported by patients. Br J Clin Pract 1994;48:5-7.
74. Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993;270:2456-2463.
75. Arroliga ME, Radojicic C, Gordon SM, et al. A prospective observational study of the effect of penicillin skin testing on antibiotic use in the intensive care unit. Infect Control Hosp Epidemiol 2003;24: 347-350.
76. Wong PF, Gilliam AD, Kumar S, et al. Regímenes antibióticos para la peritonitis secundaria de causa gastrointestinal en adultos (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus. Oxford, UK. Update Software Ltd., 2006:1.